Back to top
more

ResMed (RMD)

(Real Time Quote from BATS)

$272.85 USD

272.85
150,279

+0.25 (0.09%)

Updated Sep 17, 2025 11:12 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.64%
2Buy17.83%
3Hold9.69%
4Sell5.29%
5Strong Sell2.54%
S&P50011.29%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (87 out of 245)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Tandem Diabetes Gets Canadian Nod for t:slim X2 Insulin Pump

by Zacks Equity Research

This regulatory clearance is expected to accelerate Tandem Diabetes' (TNDM) global pump shipments and expand its customer base.

Zacks Equity Research

ResMed (RMD) Hits 52-Week High, Can the Run Continue?

by Zacks Equity Research

ResMed (RMD) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Swayta Shah headshot

5 Best Stocks With Strong Sales Growth to Buy Right Away

by Swayta Shah

Sales growth is a key measure for a company, as it helps investors understand the sustainability of its earnings growth.

Zacks Equity Research

Option Care is the Preferred Provider of Haemophilia Treatment

by Zacks Equity Research

Option Care Health (BIOS) can currently access all hemophilia factor treatments.

Zacks Equity Research

Here's Why You Should Hold GNC Holdings (GNC) Stock for Now

by Zacks Equity Research

Investors can still retain GNC Holdings (GNC) in their portfolio, thanks to solid prospects.

Zacks Equity Research

Safety Notice Issued by Boston Scientific (BSX) for AngioJet

by Zacks Equity Research

Boston Scientific (BSX) issues an urgent field safety notice for AngioJet Ultra consoles.

Zacks Equity Research

Smith & Nephew's Study Outcomes for REGENETEN Encouraging

by Zacks Equity Research

Smith & Nephew's (SNN) announces positive study outcomes for REGENETEN.

Zacks Equity Research

Zimmer (ZBH) Hits 52-Week High: What's Driving the Stock?

by Zacks Equity Research

Zimmer (ZBH) is optimistic about maintaining its growth momentum on several recent positive developments.

Zacks Equity Research

Medtronic (MDT) Beats on Q2 Earnings, Ups FY20 EPS Guidance

by Zacks Equity Research

Medtronic (MDT) demonstrates improved performances at CER, banking on growth in all major business segments and geographies.

Zacks Equity Research

Edwards Lifesciences (EW) Recalls PASCAL's Guide Sheath

by Zacks Equity Research

Edwards Lifesciences (EW) issues a product recall for its guide sheath based on report from its urgent field safety notice.

Zacks Equity Research

QIAGEN Rides on Solid QuantiFERON-TB Sales Amid Several Woes

by Zacks Equity Research

QIAGEN (QGEN) pins hopes on its key strategic collaborations with Hamilton Robotics and Tecan for the pre-analytical handling of blood tubes.

Zacks Equity Research

Amedisys Partners With nVoq to Improve Clinician Experience

by Zacks Equity Research

Amedisys (AMED) aims to enhance clinician workflow by integrating nVoq's technology platform into its home health business.

Zacks Equity Research

Canopy Growth (CGC) Q2 Earnings & Revenues Miss Estimates

by Zacks Equity Research

Canopy Growth (CGC) reports mixed fiscal second-quarter results on strength in its core segments.

Zacks Equity Research

Insulet (PODD) Hits a 52-Week High: What's Driving the Stock?

by Zacks Equity Research

Insulet (PODD) has been gaining from several positive developments recently.

Zacks Equity Research

Penumbra's (PEN) Q3 Earnings & Revenues Surpass Estimates

by Zacks Equity Research

Penumbra (PEN) witnessed strong growth across all geographies and product lines in Q3.

Zacks Equity Research

Nevro (NVRO) Q3 Loss Narrower Than Expected, Revenues Up Y/Y

by Zacks Equity Research

Nevro (NVRO) launches the Senza Omnia SCS System commercially in the United States in Q3.

Zacks Equity Research

DexCom (DXCM) Earnings and Revenues Beat Estimates in Q3

by Zacks Equity Research

DexCom's (DXCM) Q3 earnings benefit from higher revenues, solid performing Sensor and Transmitter segments and strong 2019 outlook. However, contraction in gross margin remains a woe.

Zacks Equity Research

Glaukos (GKOS) Q3 Loss Narrower Than Expected, '19 View Up

by Zacks Equity Research

Glaukos' (GKOS) Q3 revenues surge year over year. Also, the company raises 2019 revenue guidance.

Zacks Equity Research

LHC Group (LHCG) Q3 Earnings Surpass Estimates, Revenues Lag

by Zacks Equity Research

LHC Group (LHCG) third-quarter results benefit from home health and hospice admissions and higher revenues.

Zacks Equity Research

National Vision's (EYE) Q3 Earnings Top Estimates, View Raised

by Zacks Equity Research

National Vision's (EYE) third-quarter performance reflects strong growth in core business segments.

Zacks Equity Research

Option Care Health (BIOS) Q3 Earnings Meet, Revenues Top

by Zacks Equity Research

Albeit Option Care Health (BIOS) is yet to reap material benefits from its merger-related synergies, the reporting of a positive gross margin in third-quarter results is encouraging for investors.

Zacks Equity Research

DENTSPLY SIRONA (XRAY) Beats on Q3 Earnings, Ups '19 View

by Zacks Equity Research

DENTSPLY SIRONA (XRAY) gains from solid segmental contributions in Q3.

Zacks Equity Research

Globus Medical (GMED) Q3 Earnings Meet Mark, Revenue View Up

by Zacks Equity Research

Globus Medical (GMED) reports robust top-line numbers for the third quarter on segmental strength.

Zacks Equity Research

Hologic's (HOLX) Q4 Earnings Meet, Revenues Top Estimates

by Zacks Equity Research

Hologic (HOLX) exhibits robust fourth-quarter growth fueled by strong segmental performance.

Zacks Equity Research

Cardinal Health (CAH) Q1 Earnings & Revenues Beat Estimates

by Zacks Equity Research

Cardinal Health (CAH) Q1 results benefit revenue growth and strong segmental performance. However, contraction in gross margin remains a concern.